Meet Jordan

Jordan (14 years old), a real VILTEPSO patient and compensated spokesperson, and his mother, Laura.
Each patient’s experience is unique. Ask your doctor if VILTEPSO would be right for you or your loved one.*

Who is Jordan?

Jordan is a 14-year-old boy who has been taking VILTEPSO for six years. He is a real VILTEPSO patient and a compensated spokesperson. Here Jordan’s mom, Laura, answers a few of our questions about his journey with VILTEPSO.

When did Jordan start

Laura: In 2017, when Jordan was almost 8 years old, he started treatment with VILTEPSO as part of a clinical trial. Now, he is 14 years old and has had over 300 infusions!

What does Jordan like doing for fun?

Laura: He likes walking our dogs, visiting the zoo, and going to different museums. He grows his peppers in our garden and really loves cooking, especially when he gets to use his peppers! He enjoys playing board games with us as a family and video games with his friends. Lately, he’s really gotten into 3D printing and robotics.

*This describes one patient’s experience with VILTEPSO and is not intended to represent the average patient’s response. Individual patient results with VILTEPSO may vary.

Learn about VILTEPSO’s efficacy data, and the four-
year, open-label extension study

See Efficacy & Safety Data
Toggle ISI Open EXPAND


VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

For more information about VILTEPSO, see full Prescribing Information.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.